Notice of Information: NIDA offers Genotyping on Smokescreen® Genotyping Array to Substance Abuse Disorder Investigators

Notice Number: NOT-DA-16-013

Key Dates
Release Date:   February 4, 2016

Related Announcements
None    

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse is offering free genotyping for existing extracted DNA samples from people suffering from substance abuse disorders, who have consented for addiction/and or genetic studies.  The proposed samples for genotyping offered by investigators will be selected by administrative review by NIDA staff. The NIDA Center for Genetic Studies at RUDCR will do all the genotyping of samples submitted on the Smokescreen® Genotyping Array by BioRealm®.  These data once cleaned will be submitted into dbGaP, where they will be stored for a 6 month period prior to public data release per the NIH Genomic Data Sharing Policy.  During that time submitting investigators will have the chance to analyze their own data.  Once the data are released to the public there are no other time restrictions or embargo periods.

The Smokescreen® Genotyping Array by BioRealm® was created with support of a NIDA SBIR contract.  The chip consists of an Affymetrix backbone with over 800,000 SNPs.  The chip covers 98% of common genetic variation in 1000 nominated addiction genes. The chip contains 296,000 markers from African, East Asian, and European populations giving 66% coverage for people of African Ancestry, 82% for people of East Asian Ancestry, and 91 % for people of European ancestry.  In addition, 20,000 markers from expert nominations for genes posited to be associated with substance abuse and co-morbid disorders are also included on the chip. In addition, included in the array are more than 11,000 markers in the nicotine acetylcholine receptor gene clusters and nicotine metabolizing genes.  There are greater than 16,000 markers for related co-morbidities and diseases. 

Submitting a request for genotyping of extracted DNA samples

This Notice requests investigators who have relevant samples to submit a description of the number of samples, the phenotypes collected, and a description of the quality of the DNA samples. Please submit requests no later than April 1, 2016.

Requested information about DNA samples:
The DNA samples should have a DNA purity of OD260/OD280 ratio between 1.8-2.0 and OD260-OD230 ratio greater than 1.5. These DNA should be free of DNA polymerase inhibitors (i.e. heme or chelating agents). The total amount of DNA needed for genotyping is 2.5 micrograms. The DNA must not be degraded with a DNA concentration in the 50-70ng/µl range.  DNA can be extracted from whole blood and saliva but not serum or plasma.

The requested phenotypic information associated with the extracted samples should include:

Demographics
NIH PhenX Substance Abuse and Addiction measures
Behavioral/Psychosocial indicators and
Nicotine dependence measures and/or
Marijuana/Cannabis dependence measures and/or
Cocaine dependence measures and/or
Opiate dependence measures and/or
Multi-drug dependence measures and/or
Co-morbidities

The decision to accept samples for genotyping will be made administratively by NIDA Staff. If NIDA accepts the samples, genotyping will be offered gratis to the submitting investigator. 

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1309
Email: jpollock@mail.nih.gov